Small-Molecule αvβ6 Integrin Inhibitors for Oral Dosing and Selectivity
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
There is a lack of effective orally bioavailable integrin inhibitors for the treatment of various human diseases, including inflammation, fibrosis, and cancer, despite the recognized role of integrins as drug targets.
Innovation Solution
Development of compounds that inhibit αvβ6 integrin, which are selective and useful for treating conditions such as idiopathic pulmonary fibrosis, diabetic nephropathy, and solid tumors, among others, by administering therapeutically effective amounts of specific compounds.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If injectable integrin inhibitors are used, then therapeutic effectiveness is achieved, but patient compliance and convenience deteriorate
Solution Approach 1:
The patent replaces the mechanical/administrative system of injectable delivery with a chemically optimized orally bioavailable compound. The small molecule integrin inhibitors are designed to be absorbed through the gastrointestinal tract, eliminating the need for parenteral administration while maintaining therapeutic effectiveness against integrin-mediated pathologies.
Solution Approach 2:
The patent changes the bioavailability parameter of integrin inhibitors from parenteral (injectable) to oral administration. By optimizing the chemical structure of small molecule compounds, the invention achieves sufficient oral bioavailability to deliver therapeutic doses systemically, thereby improving patient convenience without sacrificing efficacy.
2Adaptability or versatility
If broad-spectrum integrin inhibitors are developed, then coverage of multiple diseases is improved, but selectivity and off-target effects worsen
Solution Approach 1:
The patent applies local quality by designing integrin inhibitors with specific binding characteristics for particular integrin heterodimers. Rather than creating a universal inhibitor that blocks all integrins, the invention develops compounds with tailored affinity and selectivity profiles that target specific integrin subtypes (such as αvβ3, αvβ5, αvβ6) involved in particular disease pathways, thereby maintaining disease coverage while improving selectivity.
Solution Approach 2:
The patent segments the integrin inhibitor portfolio into compounds with different selectivity profiles. Instead of one broad-spectrum inhibitor, the invention provides a series of specialized inhibitors, each optimized for specific integrin targets and disease indications, allowing clinicians to select the most appropriate agent for each patient's specific condition.
3Ease of operation
If oral bioavailability is improved, then patient convenience is enhanced, but molecular stability and metabolic resistance worsen
Solution Approach 1:
The patent optimizes multiple molecular parameters simultaneously to achieve the desired balance. By adjusting hydrophobicity, molecular weight, hydrogen bonding capacity, and metabolic stability features in the small molecule structures, the invention achieves sufficient oral bioavailability while maintaining adequate molecular stability and resistance to metabolic degradation.
Data Source
AI summary
Disclosed are small molecule inhibitors of αvβ6 integrin, and methods of using them to treat a number of specific diseases or conditions.